The U.S. Food and Drug Administration has slapped Novo Nordisk with a warning letter after finding the company failed to properly report serious adverse events, including three deaths, among patients who took semaglutide, the active ingredient in Wegovy and Ozempic. The March 5 letter faults the company’s post‑market safety procedures and its timelines for reporting. The move hits close to home in the Triangle, where Novo runs major manufacturing sites that produce the blockbuster weight‑loss drug and employ thousands of workers.
Triangle factories make the pill
The issue first surfaced locally in coverage from the Triangle Business Journal, which highlighted the company’s sizable U.S. footprint. Novo Nordisk operates multiple sites in the Research Triangle, according to Novo Nordisk. The company says the Wegovy pill is manufactured in North Carolina, and local coverage puts its state workforce at several thousand employees, according to Axios Raleigh.
What the FDA found
In its March 5 warning letter, the FDA said inspectors found “serious violations” of postmarketing adverse‑event rules. Written procedures allowed adverse reports to be canceled when reporters said the events were unrelated, and timelines let cases sit in medical review beyond the agency’s deadlines. The agency cited specific Argus case examples and said the lapses meant some serious and unexpected adverse events were not submitted within the required 15 calendar days. It also noted three deaths among patients taking semaglutide, including one reported suicide.
The letter warned that these findings raise “serious concerns about the scope and impact of these violations on your entire product portfolio” and directed Novo Nordisk to notify the agency in writing within 15 business days on how it plans to fix the problems, according to the FDA.
Company response and next steps
Novo Nordisk says it has already been working to correct the problems identified during the inspection and has submitted multiple updates to regulators. “Novo Nordisk takes PADE reporting requirements seriously and we plan to address the requests in the Warning Letter expeditiously and holistically,” Anna Windle, head of clinical development, medical and regulatory affairs at Novo Nordisk U.S., said in a statement, according to Fierce Pharma. The company said it is confident it can resolve the issues to the FDA’s satisfaction.
Why it matters here
The warning lands at a sensitive moment for Triangle manufacturing. Novo Nordisk has poured billions of dollars into North Carolina facilities, including a multibillion‑dollar expansion in Clayton, to boost output of semaglutide medicines, according to CNBC. Regulators’ questions about how the company tracks and reports safety information could ramp up oversight of manufacturing and supply chains that are central to local jobs and investment. The agency did not conclude that the reported adverse events were caused by the drugs, per the FDA.
What to watch
All eyes now are on the formal reply Novo Nordisk owes the agency and any follow‑up if regulators decide the written response falls short. The company has said it will address the FDA’s requests and has already supplied updates to regulators, according to Fierce Pharma, and local economic and health officials say they will monitor the situation as it develops.
